Newsletters
The Turkish Red Crescent and South Korea–based SK Plasma have signed an agreement to build Türkiye’s first plasma-derived medicine production facility, aimed at ending the country’s reliance on foreign suppliers.
According to a statement by the Turkish Red Crescent, the project marks a strategic step toward eliminating Türkiye’s external dependence on plasma-based pharmaceuticals.
The plant, to be built in Ankara’s Cubuk district, will locally manufacture vital medicines including immunoglobulin, albumin and Factor VIII.
The agreement was signed during the Türkiye-Korea Summit held in Ankara.
Turkish Red Crescent President Fatma Meric Yilmaz said the initiative represents “a very important step” in ensuring Türkiye’s self-sufficiency in critical plasma-derived treatments.
“We take great pride in undertaking this strategic investment on behalf of our nation,” she said.
SK Plasma CEO Seungjoo Kim highlighted the significance of the partnership, stating that the company is ready to share its full technical expertise to help Türkiye achieve modern production capacity in plasma-derived medicines.
The project’s key stakeholders include Turkish Red Crescent Investment and the Ministry of Industry and Technology, with SK Plasma contributing its international experience and advanced technology.
The Cubuk-based facility is expected to strengthen Türkiye’s national health care infrastructure, enhance resilience in access to essential medicines and significantly reduce dependence on foreign plasma-derived drugs.
2 min read
